The initial efficacy observed from CHECKvacc was in the context of its Phase 1 clinical trial, which primarily focused on evaluating safety and determining the optimal dose through escalation studies. It’s important to note that this phase is not designed to provide comprehensive efficacy data but rather to ensure that the treatment is safe and to explore early signals of its potential.
CHECKvacc was tested on patients who were significantly ill and had already undergone several lines of treatment, often with limited options remaining. Despite this challenging patient population, early observations were encouraging, showing promising indications of efficacy that warrant further exploration in subsequent trial phases. This initial data supports the continuation of clinical development to better understand its therapeutic impact.
(20min delay)